# Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

> **NCT05504187** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kira Pharmacenticals (US), LLC.** · enrollment: 24 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** KP104

## Key facts

- **NCT ID:** NCT05504187
- **Lead sponsor:** Kira Pharmacenticals (US), LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2026-03
- **Final completion:** 2027-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504187, "Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05504187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*